Indians Increasingly Opt for CT Coronary Angiography & TMT Tests, Reports Mahajan Imaging & Labs

IMT News Desk
IMT News Desk
· 3 min read

Over 30% growth in 2025 reflects a stronger focus on preventive care among patients and doctors, with CT Coronary Angiography promoted as a safe and low-radiation procedure supported by in-house anesthetists, cardiologists, and radiologists.

 Preventive heart health continues to gain momentum as Mahajan Imaging & Labs reports a significant rise in cardiac screening in the first eight months of 2025. The leading diagnostic chain noted sharp year-on-year growth in advanced cardiac tests, reflecting a stronger shift toward early detection and proactive healthcare.

According to the data, TMT (Treadmill Test) volumes increased by 34.6%, while CT Coronary volumes rose by 30.6% between January and August 2025 compared to the same period in 2024. Both tests are seeing wider adoption due to their effectiveness in detecting early cardiac risks. In particular, CT Coronary angiography offers a safe, non-invasive screening option with minimal radiation exposure, supported by a multidisciplinary team of radiologists, anesthetists, and cardiologists to ensure accurate and seamless results. Echocardiography also showed steady growth, rising by approximately 10%. Collectively, these trends reflect a growing awareness of preventive cardiac care among younger and middle-aged populations, as well as among clinicians who recommend timely screenings.

Kabir Mahajan, Chief Operating Officer, Mahajan Imaging & Labs, said: “We are witnessing a sustained rise in health consciousness, particularly in the 25 to 45 age group. Preventive tests like TMT and CT Coronary Angiography are seeing the fastest adoption, which shows that people are no longer waiting for symptoms; they are choosing proactive health management. CT Coronary angiography is a safe procedure with the presence of in-house anesthetists, cardiologists, and radiologists, ensuring accurate reporting and patient safety. This reflects a fundamental change in mindset, where early detection is becoming a priority over reactive treatment.”

This steady rise in preventive cardiac care marks a critical step toward easing India’s growing burden of heart disease. Experts emphasize that alongside screenings, adopting healthier habits such as regular exercise, balanced diets, and stress management remains essential to safeguarding long-term heart health.

Dr. Harsh Mahajan, Founder & Chairman, Mahajan Imaging & Labs, added: “Growing awareness about preventive health and wellness, along with rising concern over sudden cardiac deaths among young individuals, has led to an increase in people seeking heart check-ups such as TMT, echocardiography, and CT coronary angiography.

In India, coronary artery disease tends to develop much earlier than in Western populations. It is therefore advisable for individuals at high risk of heart disease to undergo their first CT coronary angiography at the age of 40 years, while those at average risk should consider it by 50 years.Current guidelines recommend repeating the scan every five years if the angiogram is normal, and earlier if narrowing of the arteries is detected, if symptoms appear, or if advised by a physician.Importantly, women too should undergo these tests, particularly after menopause since the protective effect of the hormone oestrogen on the heart is lost.”

The rise in cardiac screenings is also linked to the growing use of wearables and health-tracking apps, which allow individuals to monitor vital signs and consult doctors at the earliest signs of irregularities.

Mahajan Imaging & Labs is responding to this shift by designing AI-driven preventive cardiac screening packages for younger demographics and high-risk groups, making early detection more accessible and affordable. By addressing evolving health needs through integrated care solutions, the lab is enabling individuals and clinicians to take proactive steps toward heart health before complications arise.

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk